Eli Lilly Reports Improved Weight Loss with Combination Obesity Treatment in Mid-Stage Trial
Eli Lilly reported that its experimental combination therapy for obesity and Type 2 diabetes showed greater weight loss than a high dose of tirzepatide alone in a mid-stage trial. The regimen, combining eloralintide (targeting amylin) with low-dose tirzepatide, resulted in an average weight loss of up to 23.3%, compared to 14.8% for tirzepatide and 12.3% for eloralintide alone. The combination also reduced blood sugar levels (A1C) more effectively than either drug used separately, with a reduction of up to 2.9%. However, the treatment was associated with higher discontinuation rates due to side effects—ranging from 10.8% to 27%, depending on dose—compared to tirzepatide alone (2.9%). Lilly plans to begin Phase 3 trials by year-end and emphasized that tolerability data may improve in later stages. The results are seen as a potential breakthrough for patients who have not responded well to current GLP-1-based treatments, offering an alternative blockbuster option if the regimen proves effective and safe at scale.
Tickers: $LLY
Topics: GLP-1 drugs obesity treatment Phase 3 trials Type 2 diabetes